After More Than Four Decades at Merck KGaA, Darmstadt, Germany: Walter Galinat to Retire
Darmstadt, Germany, August 9, 2018 – The Personnel Committee of the Board of Partners of E. Merck KG, Darmstadt, Germany has resolved by best mutual agreement with Walter Galinat (62) to end his contract as a general partner of E. Merck KG, Darmstadt, Germany and Executive Board member of Merck KGaA, Darmstadt, Germany. Walter Galinat will retire with effect from September 30, 2018. As a member of the Executive Board of Merck KGaA, Darmstadt, Germany, he is currently responsible for the Darmstadt site (global company headquarters), Environment, Health, Safety, Security and Quality (EQ), Procurement, and Inhouse Consulting.
“For 42 years, Walter Galinat has been a pillar of the company. Under his leadership, the company built and grew the Liquid Crystals business to become the global market leader. The success story of this business is legendary,” said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG, Darmstadt, Germany. “The family of owners is greatly indebted to Walter Galinat for this. We genuinely wish him every success and all the very best for the next chapter of his life.”
Walter Galinat started an apprenticeship at Merck KGaA, Darmstadt, Germany in 1976 and after earning a degree in Business Administration, he moved in 1984 to Taiwan, where he built up the local subsidiary of Merck KGaA, Darmstadt, Germany. He returned to Germany in 1994, became head of the Laboratory Products division, and in 1996 assumed the leadership of Eurolab, the former laboratory distribution business of Merck KGaA, Darmstadt, Germany. In 2007, he became head of the former Liquid Crystals division and was CEO of the Performance Materials business sector from 2010 to 2017. In 2016, Walter Galinat was appointed member of the Executive Board of Merck KGaA, Darmstadt, Germany.
In the recent past, Merck KGaA, Darmstadt, Germany has transformed itself from a classic, regionally focused supplier of pharmaceuticals and chemicals into a global science and technology company. Accordingly, since the beginning of 2015 the company has been organized into three business sectors: Healthcare, Life Science and Performance Materials.
With Walter Galinat’s departure, his areas of responsibility will be assigned to the other members of the Executive Board. As of October 1, 2018, the Executive Board of Merck KGaA, Darmstadt, Germany will comprise the following members: Stefan Oschmann (Chairman), Udit Batra (CEO Life Science; IT), Kai Beckmann (CEO Performance Materials; Patents; now additionally the Darmstadt site; Inhouse Consulting), Belén Garijo (CEO Healthcare; Human Resources; now additionally EQ), and Marcus Kuhnert (CFO; now additionally Procurement).
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity.